What is LOPJLB’s current signal on INAB?

LOPJLB’s latest quantitative signal on IN8bio, Inc. (INAB) is BUY in a CRISIS regime. Signals are updated daily.

What market regime is INAB in?

IN8bio, Inc. (INAB) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does IN8bio, Inc. (INAB) do?

IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phas…

IN8bio, Inc. (INAB)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$1.18-4.07%Close

BUYCRISIS · day 2

[SCORES & PROFILE]

FUND: 11
VALUE: 18
GROWTH: 45
GARP: 6
TYPE: Balanced

Composite of Value · Growth · GARP

ROIC-54.7%

REV YoY-

ROE-91.2%

EPS YoY-

ROA-85.8%

GROSS

NET

[VALUATION]

P/E TTM-0.63

P/E FWD-

SECTOR PE20.34

INDUSTRY PE13.84

P/B1.25

P/FCF-

EV/EBITDA0.27

EV/EBIT-

PEG-

FCF YIELD-

RISK

INT COV-

D/E11.86

ALTMAN Z-

CURR RATIO8.21

ND/EBITDA-

BETA0.30

FAQ

What is LOPJLB’s current signal on INAB?: LOPJLB’s latest quantitative signal on IN8bio, Inc. (INAB) is BUY in a CRISIS regime. Signals are updated daily.
What market regime is INAB in?: IN8bio, Inc. (INAB) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does IN8bio, Inc. (INAB) do?: IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phas…

IN8bio, Inc. (INAB)

Key stats

Prediction markets

FUNDAMENTALS

Company news

FAQ